Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

被引：29

作者：

Hamlin, Paul A. ^{[1
,2
]}

Flinn, Ian W. ^{[3
]}

Wagner-Johnston, Nina ^{[4
]}

Burger, Jan A. ^{[5
]}

Coffey, Greg P. ^{[6
]}

Conley, Pamela B. ^{[6
]}

Michelson, Glenn ^{[7
]}

Leeds, Janet M. ^{[8
]}

Der, Kenneth ^{[9
]}

Kim, Yvonne ^{[10
]}

Sabalvaro-Torres, Alice ^{[11
]}

Birrell, Matt ^{[12
]}

Pandey, Anjali ^{[13
]}

Curnutte, John T. ^{[14
]}

Patel, Manish R. ^{[15
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Div Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med Coll, Dept Med, New York, NY USA

[3] Sarah Cannon Res Inst, Tennessee Oncol, Ctr Blood Canc, Nashville, TN USA

[4] Washington Univ, Div Oncol, St Louis, MO USA

[5] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA

[6] Portola Pharmaceut Inc, Biol & Pharmacol, San Francisco, CA USA

[7] Portola Pharmaceut Inc, Clin Dev, San Francisco, CA USA

[8] Portola Pharmaceut Inc, Drug Metab & Pharmacokinet, San Francisco, CA USA

[9] Portola Pharmaceut Inc, Pharmacokinet, San Francisco, CA USA

[10] Portola Pharmaceut Inc, Regulatory Affairs, San Francisco, CA USA

[11] Portola Pharmaceut Inc, Clin Operat, San Francisco, CA USA

[12] Portola Pharmaceut Inc, Corp Dev, San Francisco, CA USA

[13] Portola Pharmaceut Inc, Med Chem & Chem Dev, San Francisco, CA USA

[14] Portola Pharmaceut Inc, Res & Dev, San Francisco, CA USA

[15] Sarah Cannon Res Inst, Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 04期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; KINASE INHIBITOR; OPEN-LABEL;

D O I：

10.1002/ajh.25387

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E90 / E93

页数：4

共 6 条

[1]

Coffey GP, 2018, CLIN CANCER RES, V130, P2782

[2] The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer [J].

Coffey, Greg ;

Betz, Andreas ;

DeGuzman, Francis ;

Pak, Yvonne ;

Inagaki, Mayuko ;

Baker, Dale C. ;

Hollenbach, Stanley J. ;

Pandey, Anjali ;

Sinha, Uma .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 351 (03) :538-548

[3] An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia [J].

Sharman, Jeff ;

Hawkins, Michael ;

Kolibaba, Kathryn ;

Boxer, Michael ;

Klein, Leonard ;

Wu, Meihua ;

Hu, Jing ;

Abella, Steve ;

Yasenchak, Chris .

BLOOD, 2015, 125 (15) :2336-2343

[4] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study [J].

Stilgenbauer, Stephan ;

Eichhorst, Barbara ;

Schetelig, Johannes ;

Coutre, Steven ;

Seymour, John F. ;

Munir, Talha ;

Puvvada, Soham D. ;

Wendtner, Clemens-Martin ;

Roberts, Andrew W. ;

Jurczak, Wojciech ;

Mulligan, Stephen P. ;

Boettcher, Sebastian ;

Mobasher, Mehrdad ;

Zhu, Ming ;

Desai, Monali ;

Chyla, Brenda ;

Verdugo, Maria ;

Enschede, Sari Heitner ;

Cerri, Elisa ;

Humerickhouse, Rod ;

Gordon, Gary ;

Hallek, Michael ;

Wierda, William G. .

LANCET ONCOLOGY, 2016, 17 (06) :768-778

[5] Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment [J].

ten Hacken, Elisa ;

Burger, Jan A. .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (03) :401-413

[6] The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia [J].

Wiestner, Adrian .

HAEMATOLOGICA, 2015, 100 (12) :1495-1507

← 1 →